• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

    3/26/24 6:22:00 PM ET
    $PGTI
    $ROIV
    $RUN
    $SPGI
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGTI alert in real time by email

    NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    April 1, 2024

    S&P MidCap 400

    Addition

    Roivant Sciences

    ROIV

    Health Care



    S&P MidCap 400

    Deletion

    Sunrun

    RUN

    Industrials



    S&P SmallCap 600

    Addition

    Sunrun

    RUN

    Industrials



    S&P SmallCap 600

    Deletion

    PGT Innovations

    PGTI

    Industrials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/roivant-sciences-set-to-join-sp-midcap-400-sunrun-to-join-sp-smallcap-600-302100281.html

    SOURCE S&P Dow Jones Indices

    Get the next $PGTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGTI
    $ROIV
    $RUN
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Sunrun Inc.
    $RUN
    1/13/2026Mkt Perform
    Raymond James
    Sunrun Inc.
    $RUN
    11/10/2025$27.00Neutral → Buy
    Guggenheim
    Sunrun Inc.
    $RUN
    11/7/2025$22.00 → $23.00Buy
    TD Cowen
    Sunrun Inc.
    $RUN
    10/21/2025$26.00Neutral → Buy
    Citigroup
    Sunrun Inc.
    $RUN
    10/15/2025$19.00Underperform → Market Perform
    BMO Capital Markets
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Sunrun Inc.
    $RUN
    10/1/2025$21.00Hold → Buy
    Jefferies
    Roivant Sciences Ltd.
    $ROIV
    9/2/2025$16.00Buy
    Citigroup
    More analyst ratings

    $PGTI
    $ROIV
    $RUN
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merchants Bancorp Set to Join S&P SmallCap 600

    NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Merchants Bancorp (NASD: MBIN) will replace TreeHouse Foods Inc. (NYSE:THS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 11. Investindustrial S.A. and its affiliates are acquiring Treehouse Foods in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Feb 11, 2026 S&P SmallCap 600 Addition Merchants Bancorp MBIN Financial Feb 11, 2026 S&P SmallCap 600 Deletion TreeHouse Foods THS Consumer Staples ABOUT S&P DOW

    2/6/26 6:24:00 PM ET
    $MBIN
    $SPGI
    $THS
    Major Banks
    Finance
    Finance: Consumer Services
    Packaged Foods

    Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

    Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou

    2/6/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

    Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001)All brepocitinib 45 mg patients achieved a clinically meaningful response, with 100% demonstrating at least a 10-point improvement on CSAMI-AOn the Investigator's Global Assessment (IGA), 69% percent of brepocitinib 45 mg patients compared to 0% of placebo patients achieved the gold standard two-point improvement to "Clear" (0) or "Almost Clear" (1) (Δ 69% P=.0047)Brepocitinib 15 mg patients also improved considerably, with numerically similar improvement to the 45 mg arm on lower-bar endpoin

    2/6/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGTI
    $ROIV
    $RUN
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Sunrun

    Raymond James initiated coverage of Sunrun with a rating of Mkt Perform

    1/13/26 9:17:53 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    Sunrun upgraded by Guggenheim with a new price target

    Guggenheim upgraded Sunrun from Neutral to Buy and set a new price target of $27.00

    11/10/25 8:37:54 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    TD Cowen reiterated coverage on Sunrun with a new price target

    TD Cowen reiterated coverage of Sunrun with a rating of Buy and set a new price target of $23.00 from $22.00 previously

    11/7/25 7:49:49 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    $PGTI
    $ROIV
    $RUN
    $SPGI
    SEC Filings

    View All

    SEC Form 10-Q filed by Roivant Sciences Ltd.

    10-Q - Roivant Sciences Ltd. (0001635088) (Filer)

    2/6/26 7:31:37 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Roivant Sciences Ltd. (0001635088) (Filer)

    2/6/26 7:12:45 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

    SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    2/5/26 1:36:42 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGTI
    $ROIV
    $RUN
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jurich Lynn Michelle sold $929,741 worth of shares (50,000 units at $18.59), decreasing direct ownership by 7% to 651,175 units (SEC Form 4)

    4 - Sunrun Inc. (0001469367) (Issuer)

    2/3/26 6:08:59 PM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    President, S&P Global Mobility Eager William W exercised 254 shares at a strike of $527.79 and covered exercise/tax liability with 115 shares, increasing direct ownership by 2% to 8,863 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/3/26 4:02:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Momtazee James C was granted 609 shares and covered exercise/tax liability with 122 shares, increasing direct ownership by 0.45% to 109,030 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    1/22/26 9:00:32 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGTI
    $ROIV
    $RUN
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/18/25 7:28:11 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fenster Edward Harris bought $543,500 worth of shares (50,000 units at $10.87), increasing direct ownership by 4% to 1,408,182 units (SEC Form 4)

    4 - Sunrun Inc. (0001469367) (Issuer)

    5/13/25 7:57:16 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    $PGTI
    $ROIV
    $RUN
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    Merchants Bancorp Set to Join S&P SmallCap 600

    NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Merchants Bancorp (NASD: MBIN) will replace TreeHouse Foods Inc. (NYSE:THS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 11. Investindustrial S.A. and its affiliates are acquiring Treehouse Foods in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Feb 11, 2026 S&P SmallCap 600 Addition Merchants Bancorp MBIN Financial Feb 11, 2026 S&P SmallCap 600 Deletion TreeHouse Foods THS Consumer Staples ABOUT S&P DOW

    2/6/26 6:24:00 PM ET
    $MBIN
    $SPGI
    $THS
    Major Banks
    Finance
    Finance: Consumer Services
    Packaged Foods

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    $PGTI
    $ROIV
    $RUN
    $SPGI
    Financials

    Live finance-specific insights

    View All

    Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

    Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou

    2/6/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunrun Announces Date for Fourth Quarter and Full-year 2025 Earnings Report

    SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Sunrun (NASDAQ:RUN) today announced that it will issue its fourth quarter and full-year 2025 earnings report after the market closes on Thursday, February 26, 2026. A conference call has been scheduled to discuss these earnings results at 1:30 p.m. Pacific Time. The conference call can be accessed live via the Sunrun Investor Relations website at https://investors.sunrun.com or over the phone by dialing (877) 407-5989 (toll-free) or (201) 689-8434 (toll). An audio replay will be available following the call on the Sunrun Investor Relations website for approximately one month. A transcript of the conference call will also be posted to the Su

    1/28/26 8:00:00 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

    DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About ImmunovantImmunovant,

    1/23/26 5:25:47 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $PGTI
    $ROIV
    $RUN
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sunrun Inc.

    SC 13G/A - Sunrun Inc. (0001469367) (Subject)

    11/14/24 2:08:47 PM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13G/A filed by Sunrun Inc.

    SC 13G/A - Sunrun Inc. (0001469367) (Subject)

    11/13/24 6:57:07 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous